Search alternatives:
larger decrease » marked decrease (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
teer decrease » greater decrease (Expand Search)
a larger » a large (Expand Search), _ larger (Expand Search), _ large (Expand Search)
c large » _ large (Expand Search), a large (Expand Search), b large (Expand Search)
larger decrease » marked decrease (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
teer decrease » greater decrease (Expand Search)
a larger » a large (Expand Search), _ larger (Expand Search), _ large (Expand Search)
c large » _ large (Expand Search), a large (Expand Search), b large (Expand Search)
-
1
The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness.
Published 2025“…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …”
-
2
-
3
-
4
ECoG timescales decrease during spatial attention.
Published 2025“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”
-
5
-
6
-
7
Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers.
Published 2024“…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. (<b>B)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on day 22. …”
-
8
-
9
-
10
-
11
-
12
-
13
-
14
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
15
-
16
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
17
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
18
-
19
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
20